Pentoxifylline Treatment in Acute Pancreatitis (AP)

Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial

The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.

Participants were randomized to either the treatment group (Pentoxifylline medication) or the control group (Placebo).

Participant took a pill orally, starting from the time of admission. Participants received a total of 9 doses over the three days of hospitalization (72 hours).

Research blood draws were done at baseline and on 5 successive days or until the time of discharge, whichever occured earlier. The study gathered clinical follow up information up to 4 months following hospitalization regarding the diagnosis of acute pancreatitis.

Inclusion criteria

• Enrollment within 72 hours of diagnosis of acute pancreatitis (AP)
• Ability to give informed consent or a Legal Adult Representative (LAR) able to give informed consent for subject when needed as defined buy LAR use guidelines.
• Adult subjects of age ≥18 years.

Exclusion Criteria:

• Moderate or severe congestive heart failure
• History of seizure disorders or demyelinating disease
• Nursing mothers
• Pregnancy
• History of prior tuberculosis or risk factors for tuberculosis
• Evidence of non- corticosteroid immunosuppression (such as malignancy, chronic renal failure, chemotherapy within 60 days, and HIV)
• Evidence of active hemorrhage
• Paralytic ileus with severe nausea and vomiting